Genprex, Inc. Material Event - What Happened

Hey there! Let's break down what's going on with Genprex, Inc. in a way that makes sense, without all the confusing finance talk. Think of this as me explaining the news to you over a cup of coffee.

---

1. What happened? (The actual event, in plain English)

Genprex, Inc. announced that they believe they have successfully raised enough money to meet Nasdaq's minimum stockholders' equity requirement. This is a big deal because it means they think they've avoided being delisted from the Nasdaq stock exchange, which was a real possibility. They've been working to get back in line with Nasdaq's Listing Rule 5550(b)(1), which basically says a company needs to have a certain amount of money (stockholders' equity) to stay listed.

They managed to do this by raising funds through a few different ways:

• Registered direct offerings: These are specific sales of stock directly to investors.
• "At the market" offering: This allows them to sell shares directly into the market over time.
• Equity line of credit: This is like a credit line, but instead of borrowing cash, they can issue new shares to get funds.

However, it's important to note that the Nasdaq Hearings Panel (the group that makes these decisions) hasn't officially confirmed yet that Genprex is back in compliance. So, while Genprex is optimistic, the final word isn't out.

2. When did it happen?

Genprex filed a report on December 23, 2025, stating their belief that they've regained compliance.

This event is the culmination of a few earlier developments:

• August 19, 2025: Genprex first received a letter from Nasdaq saying they weren't meeting the minimum stockholders' equity requirement.
• October 24 and October 29, 2025: They closed their registered direct offerings, which helped raise a significant portion of the necessary funds.
• November 25, 2025: The Nasdaq Hearings Panel gave Genprex an extension until December 31, 2025, to show they could meet the requirement.

3. Why did it happen? (The backstory and context)

Genprex was in a bit of a bind because they weren't meeting one of Nasdaq's key rules for staying listed on the stock exchange – specifically, the rule about having enough stockholders' equity. This is a common challenge for smaller biotech companies that are investing heavily in research and development and might not be profitable yet.

If they didn't fix this, their stock could have been delisted from Nasdaq. Delisting would be a major blow, making it harder for them to raise money in the future, hurting their reputation, and making it more difficult for investors to trade their stock. So, they actively worked to raise capital to boost their equity and avoid this outcome.

4. Why does this matter? (The "so what?" and significance)

This is a really important development for Genprex.

• Positive: If Nasdaq officially confirms their compliance, it means Genprex has successfully navigated a serious threat to its public listing. This removes a major cloud of uncertainty over the company, which is good for investor confidence and allows them to continue trading on a major exchange. It shows they can raise capital when needed.
• Uncertainty: The key here is that Nasdaq hasn't officially confirmed it yet. So, while Genprex is confident, there's still a lingering risk until the Panel makes its final decision.
• Overall: Staying listed on Nasdaq is crucial for Genprex's ability to fund its drug development and operate as a public company. This event is a critical step in securing that status.

5. Who is affected?

• Genprex Investors (that's you!): This news directly impacts the stability and future of your investment. If compliance is confirmed, it's a positive sign. If not, the stock could face significant challenges. The uncertainty until Nasdaq's official word means the stock could still be volatile.
• Genprex Employees: Maintaining the Nasdaq listing helps ensure the company's stability and ability to continue its operations, which is good for job security and morale.
• Genprex as a Company: Its ability to raise capital, maintain its public profile, and attract future investors depends heavily on staying listed on a reputable exchange like Nasdaq.
• Patients and the Medical Community: While not directly impacted by this financial event, the company's ability to fund its research and bring potential new treatments to market relies on its financial health and access to capital.

6. What happens next? (Immediate and future implications)

Okay, so now that this has happened, what's next on the horizon?

• Immediately: The most important next step is for the Nasdaq Hearings Panel to review Genprex's current financial situation and make an official determination on whether they have indeed regained compliance with the Stockholders' Equity Requirement. Genprex will be waiting for this decision.
• In the Future: If Nasdaq confirms compliance, Genprex can then fully focus its efforts and newly raised capital on its core mission: advancing its clinical trials, developing its experimental cancer drug Oncoprex, and working towards getting it approved and to market. If, for some reason, Nasdaq doesn't confirm compliance, Genprex would face further challenges regarding its listing status.

7. What should investors/traders know? (Practical takeaways)

For those of you watching the stock, here's what to keep in mind:

• Not a Done Deal (Yet): While Genprex believes it's compliant, the official word from Nasdaq is still pending. This means there's still a level of uncertainty.
• Volatility: News like this, especially with a pending decision, can make the stock price jump around. Be prepared for potential ups and downs as the market reacts to the company's announcement and awaits Nasdaq's final decision.
• Watch for Official Confirmation: The next big news event will be the announcement from the Nasdaq Hearings Panel regarding their decision. This will be a significant catalyst for the stock.
• Importance of Listing: Staying on Nasdaq is crucial for Genprex's credibility, its ability to attract investors, and the liquidity of its stock. Successfully resolving this issue is a major positive for the company's long-term viability.